BAC vs PFE: Which Is the Better Buy?
Side-by-side comparison of Bank of America Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-14.
Bank of America Corporation · Financial Services
$59.50
-45.0% upside to fair value
Grade C
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
BAC trades at a lower forward P/E
(14.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BAC |
PFE |
| Current Price |
$59.50 |
$25.22 |
| Fair Value Estimate |
$32.73 |
$25.92 |
| Upside to Fair Value |
-45.0%
|
+2.8%
|
| Market Cap |
$422.2B |
$143.7B |
| Forward P/E |
14.6x
|
19.2x
|
| EV / EBITDA |
13.3x
|
12.3x
|
| Price / Sales |
2.4x
|
2.3x
|
| Price / FCF |
7.5x
|
15.2x
|
| Revenue Growth YoY |
-35.6%
|
+5.4%
|
| Gross Margin |
63.2%
|
69.3%
|
| Operating Margin |
22.9%
|
23.4%
|
| Return on Equity |
10.5%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
13.4%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Bank of America Corporation operates as a diversified bank within the financial services sector, offering a broad range of banking and financial products. The business quality is medium, supported by a 10.5% return on equity and solid margins, but recent revenue declined sharply by 35.6% in the most recent quarter, indicating top-line pressure. Despite earnings growth of 16.1% in the same period,…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
BAC |
PFE |
| Zone Low |
$24.55 |
$19.44 |
| Zone High |
$27.82 |
$22.03 |
| In Buy Zone? |
No
|
No
|